De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Xenetic Biosciences Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Jim Parslow
Algemeen directeur
US$433.7k
Totale compensatie
| Percentage CEO-salaris | 75.9% |
| Dienstverband CEO | 7.5yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | 5.6yrs |
Recente managementupdates
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable
Dec 15
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
Dec 01Recent updates
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable
Dec 15Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
Dec 01Xenetic Biosciences reports Q2 results
Aug 12Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer
Aug 02Xenetic inks clinical manufacturing contract with Catalent
Jul 07Xenetic Biosciences reports Q3 results
Nov 13Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$5m |
| Mar 31 2024 | n/a | n/a | -US$4m |
| Dec 31 2023 | US$434k | US$329k | -US$4m |
| Sep 30 2023 | n/a | n/a | -US$4m |
| Jun 30 2023 | n/a | n/a | -US$4m |
| Mar 31 2023 | n/a | n/a | -US$6m |
| Dec 31 2022 | US$474k | US$329k | -US$7m |
| Sep 30 2022 | n/a | n/a | -US$7m |
| Jun 30 2022 | n/a | n/a | -US$7m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$521k | US$299k | -US$6m |
| Sep 30 2021 | n/a | n/a | -US$5m |
| Jun 30 2021 | n/a | n/a | -US$11m |
| Mar 31 2021 | n/a | n/a | -US$11m |
| Dec 31 2020 | US$359k | US$285k | -US$11m |
| Sep 30 2020 | n/a | n/a | -US$11m |
| Jun 30 2020 | n/a | n/a | -US$14m |
| Mar 31 2020 | n/a | n/a | -US$14m |
| Dec 31 2019 | US$388k | US$265k | -US$18m |
| Sep 30 2019 | n/a | n/a | -US$19m |
| Jun 30 2019 | n/a | n/a | -US$10m |
| Mar 31 2019 | n/a | n/a | -US$11m |
| Dec 31 2018 | US$288k | US$265k | -US$7m |
| Sep 30 2018 | n/a | n/a | -US$1m |
| Jun 30 2018 | n/a | n/a | -US$2m |
| Mar 31 2018 | n/a | n/a | -US$3m |
| Dec 31 2017 | US$960k | US$199k | -US$4m |
Compensatie versus markt: De totale vergoeding ($USD 433.73K ) Jim } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).
Compensatie versus inkomsten: De vergoeding van Jim is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Jim Parslow (59 yo)
7.5yrs
Tenure
US$433,732
Compensatie
Mr. James F. Parslow, also known as Jim, has been Chief Financial Officer at Xenetic Biosciences, Inc. since April 03, 2017 and serves as its Chief Operating Officer and Corporate Secretary and serves as i...
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President & Director | 8.3yrs | US$563.49k | 0% $ 0 | |
| Independent Chairman of the Board | 7.2yrs | US$57.54k | 0% $ 0 | |
| Independent Director | 8.7yrs | US$57.54k | 0% $ 0 | |
| Independent Director | 10.8yrs | US$57.54k | 0% $ 0 | |
| Independent Director | 7.2yrs | US$57.54k | 0% $ 0 | |
| Non-Executive Director | less than a year | geen gegevens | 4.44% $ 295.8k | |
| Member of Scientific Advisory Board | 5.4yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 5.8yrs | geen gegevens | geen gegevens | |
| Independent Director | 5.3yrs | US$57.54k | geen gegevens | |
| Independent Non-Executive Director | 5.1yrs | US$57.54k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.7yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 2.4yrs | geen gegevens | geen gegevens |
5.6yrs
Gemiddelde duur
57.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van XBIO wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.6 jaar).